Insmed (NASDAQ:INSM – Free Report) had its price objective increased by HC Wainwright from $230.00 to $245.00 in a report released on Thursday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.
A number of other equities research analysts also recently issued reports on INSM. Citigroup reissued an “outperform” rating on shares of Insmed in a research report on Thursday, December 18th. Royal Bank Of Canada lifted their price objective on Insmed from $197.00 to $200.00 and gave the company an “outperform” rating in a report on Wednesday, January 21st. Jefferies Financial Group began coverage on Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 target price for the company. Wells Fargo & Company reduced their target price on Insmed from $208.00 to $175.00 and set an “overweight” rating on the stock in a report on Monday. Finally, Leerink Partners raised their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a research report on Tuesday. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Insmed presently has an average rating of “Buy” and a consensus target price of $210.19.
Check Out Our Latest Stock Report on Insmed
Insmed Stock Performance
Insmed (NASDAQ:INSM – Get Free Report) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.47). Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The business had revenue of $263.84 million for the quarter, compared to the consensus estimate of $263.97 million. During the same period in the prior year, the business posted ($1.32) earnings per share. The firm’s revenue for the quarter was up 152.6% compared to the same quarter last year. Analysts anticipate that Insmed will post -4.56 earnings per share for the current year.
Insider Activity at Insmed
In other news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the completion of the transaction, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. This represents a 67.64% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William Lewis sold 19,215 shares of the stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total value of $3,247,335.00. Following the completion of the transaction, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. The trade was a 5.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 189,651 shares of company stock valued at $31,533,654. 3.00% of the stock is owned by insiders.
Institutional Investors Weigh In On Insmed
Hedge funds and other institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC grew its holdings in shares of Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the last quarter. Kingsview Wealth Management LLC raised its holdings in Insmed by 2.7% in the 3rd quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 60 shares during the last quarter. Choreo LLC raised its holdings in Insmed by 2.9% in the 3rd quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after buying an additional 65 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 69 shares during the period. Finally, ORG Partners LLC boosted its position in Insmed by 12.7% during the 4th quarter. ORG Partners LLC now owns 657 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 74 shares during the period.
Key Headlines Impacting Insmed
Here are the key news stories impacting Insmed this week:
- Positive Sentiment: Positive Phase 3b ENCORE topline results for ARIKAYCE in MAC lung disease — a clear clinical win that strengthens the commercial and regulatory narrative for the lung‑disease franchise. Insmed reports positive topline results from phase 3b ENCORE study of Arikayce in patients with MAC lung disease
- Positive Sentiment: HC Wainwright raised its price target to $245 and maintained a Buy rating—one of the most bullish analyst moves, implying meaningful upside versus the current share price. Benzinga
- Positive Sentiment: Stifel increased its price target to $208, and Mizuho lifted its target to $206 (Outperform), providing additional analyst support behind the stock’s recovery narrative. Stifel Nicolaus Boosts Insmed (NASDAQ:INSM) Price Target to $208.00
- Positive Sentiment: Analysts at Leerink Partners and Bank of America signaled that the stock is likely to rise, reinforcing the post‑trial optimism among sell‑side firms. Insmed (NASDAQ:INSM) Stock Price Expected to Rise, Leerink Partners Analyst Says
- Neutral Sentiment: Insmed hosted a shareholder/analyst call with a slide deck summarizing results and commercial strategy — useful for modeling uptake but not a headline catalyst by itself. Insmed Incorporated (INSM) Shareholder/Analyst Call – Slideshow
- Neutral Sentiment: CEO interviews and videos (coverage on MSN/other outlets) reiterate commercial opportunity and Japan market size, helpful color for adoption expectations. Insmed CEO on its Arikayce drug after shares surge on trial results
- Negative Sentiment: Wells Fargo trimmed its price target to $175, which introduces a more conservative valuation reference and may limit near‑term upside for some investors. Wells Fargo & Company Lowers Insmed (NASDAQ:INSM) Price Target to $175.00
About Insmed
Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.
The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.
Further Reading
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.
